Market Report Source

Overview

Introduction

ArQule, founded as a chemistry service company, became a drug discovery and development company by acquiring Cyclic Pharmaceuticals in 2003. The company’s proprietary drug discovery platforms such as Cancer Survival Pathways and Activated Checkpoint Therapy have helped it building a product pipeline.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. It’s product pipeline includes: ARQ 501 in Phase II for sarcoma, head and neck cancer and pancreatic cancer; ARQ 171 in Phase I for cancer; and ARQ 197 in Phase II for the treatment of solid tumors and pancreatic cancer. The company recognizes revenues in the form of collaboration fees and milestone payments from the companies with which it has entered into collaboration agreements with Roche and Wyeth. The company’s total revenues increased during 2004-2006, from $5 million to $6.6 million. The company’s only contributor to revenue growth during 2004-2006 was revenues received under license and collaboration agreements with Roche and Wyeth.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization.

Table of Contents

Overview
Catalyst
Summary
Company Structure
Company Overview and Key Facts
Business Description
History
Locations and Subsidiaries
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Business Segment Performance
Products & Services
Pipeline Products
AC Forecast Product Sales
Competitors and Strategic Business Relationships
Key Competitors
Key Clients
Shareholding Structure
Strategy
Company View
Corporate Strategy
SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Value Chain Analysis
Overview
Discovery and Product Development
Scorecard
Overview
Scorecard Analysis
Key Employees
List of Key Employees
Key Employee Biographies
Financial and Operational Overview
Financial and Operational Overview

APPENDIX
Ask the analyst
Datamonitor consulting
Disclaimer

FIGURES
Figure 1: ArQule – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)

TABLES
Table 1: ArQule – Key Facts
Table 2: ArQule – Locations and Subsidiaries
Table 3: ArQule – Year-End Share Price and Market Capitalization, 2002-2006 ($)
Table 4: ArQule – Key Events Impacting Share Price Performance
Table 5: ArQule – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table 6: ArQule – Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
Table 7: ArQule – Balance Sheet, 2002-2006 ($ Mn)
Table 8: ArQule – Cash Flow, 2002-2006 ($ Mn)
Table 9: ArQule – Revenue Breakdown by Division, 2002-2006 ($ Mn)
Table 10: ArQule – In -House Products
Table 11: ArQule – Collaboration Products
Table 12: ArQule – Forecast Sales, 2006-2010 ($ Mn)
Table 13: ArQule – Key Competitors
Table 14: ArQule – Key Clients
Table 15: ArQule – Key Shareholders
Table 16: ArQule – SWOT Analysis Summary
Table 17: ArQule – Value Chain Analysis
Table 18: ArQule – Scorecard
Table 19: ArQule – Key Employees
Table 20: ArQule – Financial and Operational Overview